Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Colorectal Neoplasms 442 Stomach Neoplasms 290 Rectal Neoplasms 266 Colonic Neoplasms 191 Pancreatic Neoplasms 175 Neoplasm Metastasis 110 Esophageal Neoplasms 87 Neoplasms 68 Carcinoma, Hepatocellular 59 Adenocarcinoma Of Esophagus 47 Adenocarcinoma 46 Lymphoma, Large B-Cell, Diffuse 44 Cholangiocarcinoma 44 Carcinoma, Non-Small-Cell Lung 41 Biliary Tract Neoplasms 37 Gallbladder Neoplasms 30 Gastrointestinal Neoplasms 29 Recurrence 25 Liver Neoplasms 24 Ovarian Neoplasms 23 Esophageal Squamous Cell Carcinoma 23 Breast Neoplasms 22 Peritoneal Neoplasms 17 Bile Duct Neoplasms 17 Unspecified Adult Solid Tumor, Protocol Specific 16 Parkinson Disease 4, Autosomal Dominant Lewy Body 14 Locally Advanced Rectal Cancer 13 Head and Neck Neoplasms 13 Lung Neoplasms 12 Lymphoma, Non-Hodgkin 11

Interventions

Temozolomide 1 S 1 (combination) 1 Oxaliplatin 1 Nivolumab 1 Capecitabine 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Pan-tumor × Oxaliplatin × Clear all

NCT04566380 2025-06-03

ONO-4538 Phase II Rollover Study (ONO-4538-98)

Ono Pharmaceutical Co., Ltd.

Phase 2 Recruiting

Pan-tumor

Data powered by HemOnc (CC BY 4.0) Colophon ⚡